Evidence map›Paper›PMID 30797639›Full record

ArticleVaccine2019

Differential durability of immune responses to measles and mumps following MMR vaccination.

Richard B Kennedy, Inna G Ovsyannikova, Antonia Thomas, Beth R Larrabee, Steven Rubin, Gregory A Poland

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Richard B KennedyMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: kennedy.rick@mayo.edu.
Inna G OvsyannikovaMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Antonia ThomasCenter for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.
Beth R LarrabeeDivision of Biomedical Statistics and Informatics, Department of Health Science Research, Mayo Clinic, Rochester, MN 55905, USA.
Steven RubinCenter for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.
Gregory A PolandMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clinic in Florida · USCenter for Biologics Evaluation and Research · USMayo Clinic · US

Funding

The Immunogenetics of Measles ImmunityR01AI033144 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 1993 to 2022
$8.1M
Systems Biology of Mumps Vaccine ResponseR01AI138965 · NIAID · MAYO CLINIC ROCHESTER · PI KENNEDY, RICHARD B · 2018 to 2022
$3.9M
Understanding measles vaccine failure (and success) in Southern IndiaR01AI121054 · NIAID · MAYO CLINIC ROCHESTER · PI JACOB, JOSHY, KENNEDY, RICHARD B · 2017 to 2021
$3.8M
Genetic Markers of Long-Term Mumps Vaccine ImmunityR01AI127365 · NIAID · MAYO CLINIC ROCHESTER · PI KENNEDY, RICHARD B · 2016 to 2020
$3.6M
NIAID NIH HHS R01 AI033144NIAID NIH HHS R01 AI121054NIAID NIH HHS R01 AI127365NIAID NIH HHS R01 AI138965
6 · The paper itself

Abstract

The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II® vaccination, in a cohort of 98 healthy adults. Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.

Indexed as

ImmunityAdolescentAntibodies, NeutralizingAntibodies, ViralChildFemaleHost-Pathogen InteractionsHumansImmunity, CellularImmunity, HumoralImmunization ScheduleImmunization, SecondaryMaleMeaslesMeasles-Mumps-Rubella VaccineMumpsAntibodies, NeutralizingAntibodies, ViralMeasles-Mumps-Rubella VaccineAntibodiesCell-mediated immunityHumoral immunityMeaslesMeasles vaccineMeasles virusMMR-II vaccineMumpsMumps vaccineMumps virusT cell ELISPOT

Identifiers

PMID30797639
PMCPMC6414234
OpenAlexW2915635060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.